bluuebunny/crossref_metadata_2025_split huggingface dataset:
Implementasi Pelaksanaan Pendidikan Inklusi di Sekolah Reguler Kota Bandung
Authors: Madyaning Ratri Titis , Nenden Ineu Herawati  
Published: February 2024

Pendidikan merupakan hak dasar setiap warga Negara Indonesia, termasuk mereka yang berkebutuhan khusus. Adanya layanan pendidikan inklusi merupakan sistem penyelenggaraan pendidikan yang memberikan layanan dan kesempatan kepada semua anak tidak terkecuali anak berkebutuhan khusus dan anak dengan potensi kecerdasan atau bakat istimewa untuk mengikuti pendidikan dan pembelajaran dalam satu lingkungan bersama-sama anak dengan kriteria pada umumnya. Penelitian ini mengkaji dan mendeskripsikan implementasi pelaksanaan pendidikan inklusi di sekolah reguler Kota Bandung yakni SDN 029 Cilengkrang Kota Bandung dengan partisipan peserta didik inklusi yang berjumlah 23 orang. Penelitian ini menggunakan metode deskriptif – kualitatif, melalui pendekatan studi kasus. Adapun hasil penelitian yang telah dilakukan ialah dalam pemenuhan kebutuhan belajar bagi peserta didik diperlukan sebuah program pendidikan inklusi yakni sebuah sistem pendidikan yang memberikan kesempatan bagi peserta didik berkebutuhan khusus untuk mengikuti pembelajaran di lingkungan pendidikan yang sama dengan peserta didik normal lainnya. Dalam menjalankan program Pendidikan inklusi tentunya tidak semudah membalikkan tangan diperlukan adanya kominten bersama serta kolaborasi antar warga sekolah juga dinas terkait guna menciptakan lingkungan belajar yang bermakna, nyaman, dan tentunya menyenangkan bagi peserta didik berkebutuhan khusus.
CLUSTERING DATA METEOROLOGI WILAYAH INDONESIA TIMUR DENGAN METODE K-MEANS DAN FUZZY C-MEANS
Authors: Andrian Gion , Arisandi Desi , Handhayani Teny 
Published: February 2024

Climate change is a global issue that affect human life and the environment. Signs of climate change can be observed from long-term meteorological data. This research uses clustering techniques with the K-Means and Fuzzy C-Means methods to group cities in the Eastern Indonesia region based on numerical daily time series meteorological data from 1 January 2010 to 31 August 2023. The variables are minimum temperature, maximum temperature, temperature average, humidity, rainfall, duration of sunlight, maximum wind speed, and average wind speed. The dataset was collected from 28 meteorological stations. The K-Means and Fuzzy C-Means methods obtained the same results, namely the highest silhouette value of 0.218 with the number of clusters k = 2. In general, the annual trend shows an increase in temperature and a decrease in wind speed which are signs of climate change. This research is an early study of climate change in East Indonesia. The results of this research are expected to contribute to the study of climate change in Indonesia.
Performance evaluation of Moringa oleifera seeds aqueous extract for removing Microcystis aeruginosa and microcystins from municipal treated-water
Authors: Alhaithloul Haifa A. S. , Mohamed Zakaria A. , Saber Abdullah A. , Alsudays Ibtisam Mohammed , Abdein Mohamed A. , Alqahtani Mesfer M. , AbuSetta Noha G. , Elkelish Amr , Pérez Leonardo Martín , Albalwe Fauzeya Mateq , Bakr Asmaa A. 
Published: February 2024

Introduction: Toxic microcystins (MCs) produced by cyanoprokaryotes -particularly by the cosmopolitan cyanobacterium Microcystis aeruginosa- pose adverse effects on aquatic organisms and their ecosystem and may also cause serious impacts on human health. These harmful monocyclic heptapeptides are the most prevalent cyanotoxins reported in freshwaters and must be eliminated for avoiding MCs release in receiving water bodies. Hence, this work aimed to test the efficacy of Moringa oleifera seeds water-based extract (MO) as a natural coagulant for removing cyanobacteria (especially M. aeruginosa), microalgae, and its associated MCs from pre-treated municipal wastewaters.Methodology: Four different MO coagulant doses (25, 50, 75 and 100 mg L−1) were investigated for cyanobacteria and microalgae removal by conventional coagulation assays and morphology-based taxonomy studies. Additionally, water turbidity and chlorophyll a (Chl a) content were also determined. Further, the presence and concentration of MCs soluble in water, remaining in the particulate fraction, and flocculated within the residual sludge were assessed using high-performance liquid chromatography coupled with diode array detection (HPLC-DAD).Results: The treatment with MO at 100 mg L−1 substantially reduced the number of cyanobacterial and microalgal species in the treated samples (average removal rate of 93.8% and 86.9%, respectively). These results agreed with a ∼44% concomitant reduction in Chl a and ∼97% reduction in water turbidity (a surrogate marker for suspended solids content). Notably, MCs concentrations in the treated water were significantly lowered to 0.6 ± 0.1 µg L−1 after addition of 100 mg L−1 MO. This value is below the WHO recommended limits for MCs presence in drinking water (&lt;1.0 µg L−1).Discussion: The present study provides promising insights into the applicability of MO as a cost-effective, reliable, and sustainable natural coagulant, particularly for using in developing countries, to eliminate harmful cyanobacteria and cyanotoxins in municipal water treatment facilities.
Effects of menstrual cycle on hemodynamic and autonomic responses to central hypovolemia
Authors: Shankhwar Vishwajeet , Urvec Janez , Steuber Bianca , Schmid Zalaudek Karin , Saloň Adam , Hawliczek Anna , Bergauer Andrej , Aljasmi Khawla , Abdi Asrar , Naser Asmaa , Himeidi Maya , Alsuwaidi Hanan , Du Plessis Stefan , Alsheikh-Ali Alawi , Kellett Catherine , Bayoumi Riad , Blaber Andrew Phillip , Goswami Nandu 
Published: February 2024

BackgroundEstrogen and progesterone levels undergo changes throughout the menstrual cycle. Existing literature regarding the effect of menstrual phases on cardiovascular and autonomic regulation during central hypovolemia is contradictory.Aims and studyThis study aims to explore the influence of menstrual phases on cardiovascular and autonomic responses in both resting and during the central hypovolemia induced by lower body negative pressure (LBNP). This is a companion paper, in which data across the menstrual phases from healthy young females, whose results are reported in Shankwar et al. (2023), were further analysed.MethodsThe study protocol consisted of three phases: (1) 30 min of supine rest; (2) 16 min of four LBNP levels; and (3) 5 min of supine recovery. Hemodynamic and autonomic responses (assessed via heart rate variability, HRV) were measured before-, during-, and after-LBNP application using Task Force Monitor® (CNSystems, Graz, Austria). Blood was also collected to measure estrogen and progesterone levels.ResultsIn this companion paper, we have exclusively assessed 14 females from the previous study (Shankwar et al., 2023): 8 in the follicular phase of the menstrual cycle (mean age 23.38 ± 3.58 years, height 166.00 ± 5.78 cm, weight 57.63 ± 5.39 kg and BMI of 20.92 ± 1.96 25 kg/m2) and 6 in the luteal phase (mean age 22.17 ± 1.33 years, height 169.83 ± 5.53 cm, weight 62.00 ± 7.54 kg and BMI of 21.45 ± 2.63 kg/m2). Baseline estrogen levels were significantly different from the follicular phase as compared to the luteal phase: (33.59 pg/ml, 108.02 pg/ml, respectively, p &lt; 0.01). Resting hemodynamic variables showed no difference across the menstrual phases. However, females in the follicular phase showed significantly lower resting values of low-frequency (LF) band power (41.38 ± 11.75 n.u. and 58.47 ± 14.37 n.u., p = 0.01), but higher resting values of high frequency (HF) band power (58.62 ± 11.75 n.u. and 41.53 ± 14.37 n.u., p = 0.01), as compared to females in the luteal phase. During hypovolemia, the LF and HF band powers changed only in the follicular phase F(1, 7) = 77.34, p &lt; 0.0001 and F(1, 7) = 520.06, p &lt; 0.0001, respectively.ConclusionsThe menstrual phase had an influence on resting autonomic variables, with higher sympathetic activity being observed during the luteal phase. Central hypovolemia leads to increased cardiovascular and autonomic responses, particularly during the luteal phase of the menstrual cycle, likely due to higher estrogen levels and increased sympathetic activity.
Asymmetric growth-limiting development of the female conceptus
Authors: Estrella Consuelo Amor S. , Gatford Kathryn L. , Xiang Ruidong , Javadmanesh Ali , Ghanipoor-Samami Mani , Nattrass Greg S. , Shuaib Entesar , McAllister Milton M. , Beckman Ian , Thomsen Dana A. , Clifton Vicki L. , Owens Julie A. , Roberts Claire T. , Hiendleder Stefan , Kind Karen L. 
Published: February 2024

IntroductionSex differences in prenatal growth may contribute to sex-dependent programming effects on postnatal phenotype. MethodsWe integrated for the first time phenotypic, histomorphological, clinico-chemical, endocrine and gene expression analyses in a single species, the bovine conceptus at mid-gestation. ResultsWe demonstrate that by mid-gestation, before the onset of accelerated growth, the female conceptus displays asymmetric lower growth compared to males. Female fetuses were smaller with lower ponderal index and organ weights than males. However, their brain:body weight, brain:liver weight and heart:body weight ratios were higher than in males, indicating brain and heart ‘sparing’. The female placenta weighed less and had lower volumes of trophoblast and fetal connective tissue than the male placenta. Female umbilical cord vessel diameters were smaller, and female-specific relationships of body weight and brain:liver weight ratios with cord vessel diameters indicated that the umbilico-placental vascular system creates a growth-limiting environment where blood flow is redistributed to protect brain and heart growth. Clinico-chemical indicators of liver perfusion support this female-specific growth-limiting phenotype, while lower insulin-like growth factor 2 (IGF2) gene expression in brain and heart, and lower circulating IGF2, implicate female-specific modulation of key endocrine mediators by nutrient supply. ConclusionThis mode of female development may increase resilience to environmental perturbations in utero and contribute to sex-bias in programming outcomes including susceptibility to non-communicable diseases.
Efficacy of pasireotide LAR for acromegaly: a prolonged real-world monocentric study
Authors: Favero Vittoria , Zampetti Benedetta , Carioni Emanuela I. , Dalino Ciaramella Paolo , Grossrubatscher Erika , Dallabonzana Daniela , Chiodini Iacopo , Cozzi Renato 
Published: February 2024

BackgroundAcromegaly is caused by excessive growth hormone (GH) and insulin-like growth factor 1 (IGF1). Medical therapy plays a role as a treatment option for persistent disease after non-curative surgery or as a first-line therapy when surgery is not feasible. Pasireotide-LAR (Pas-LAR) is recommended for patients with acromegaly as second-line treatment.AimTo evaluate the patients characteristics predictive of an adequate response to Pas-LAR and the long-term efficacy and safety of the Pas-LAR treatment.MethodsData from 19 patients with active acromegaly, who were and resistant or intolerant to first-line medical therapy and were switched to pas-LAR have been retrospectively collected. We compared the baseline clinical and biochemical characteristics of patients who were found to respond to Pas-LAR therapy (responders, n=14) with those of patients who did not respond (non-responders, n=5). We then evaluated the Pas-LAR efficacy and safety during long-term follow-up in responders.ResultsIGF1 normalization occurred in 71.4% of responders after one injection. IGF1 levels, [median(interquartile range) of the upper limit of the normal range (ULN) fold increase] were higher in non-responders compared to responders within the initial month of therapy [1.40(1.30-2.34) vs 0.70(0.55-1.25), respectively, p=0.009] and after three [1.77(1.74-2.29) vs 0.94(0.82-1.13), respectively, p=0.029] and six months [1.68(1.33-1.72) vs 1.00(0.65 -1.28), respectively, p=0.002]. Out of 6 patients with symptomatic headache (all in responder group), 5 and 1 reported the resolution and improvement of headache, respectively, already after the first injection. Median HbA1c levels tended to increase from baseline to 6 months both in responder (36 mMol/Mol to 42 mMol/Mol) and non-responder patients (45 mMol/Mol to 48 mMol/Mol). During long term follow up, in the responder group 2 new patients developed diabetes. Tumor shrinkage was observed in 6 out of 7 evaluated responders, with no cases of size increase during the long-term follow-up.ConclusionPas-LAR is effective and safe and the early identification of responders is possible just after the first administration.
Fraction of exhaled nitric oxide is higher in liver transplant recipients than in controls from the general population: a cohort study
Authors: Arentoft Nicoline S. , Fialla Annette D. , Krohn Paul S. , Patursson Magda T. , Thudium Rebekka F. , Suarez-Zdunek Moises A. , Høgh Julie , Lauridsen Emilie H. E. , Hansen Jesper B. , Jensen Jens-Ulrik S. , Perch Michael , Møller Dina L. , Pommergaard Hans-Christian , Aagaard Niels K. , Davidsen Jesper R. , Lange Peter , Çolak Yunus , Afzal Shoaib , Nordestgaard Børge G. , Rasmussen Allan , Nielsen Susanne D. 
Published: February 2024

BackgroundFraction of exhaled nitric oxide with an expiratory flow of 50 mL/s (FENO50) is a biomarker of eosinophilic airway inflammation. Liver transplant recipients have an increased risk of pulmonary infections, but little is known about the burden of chronic pulmonary diseases in this group. We aimed to assess the prevalence of elevated FENO50 in liver transplant recipients and compare it to controls from the general population.MethodsFENO50 was measured in 271 liver transplant recipients from The Danish Comorbidity in Liver Transplant Recipients (DACOLT) study and 1,018 age- and sex-matched controls from The Copenhagen General Population Study (CGPS). Elevated FENO50 was defined as ≥25 or ≥50 parts per billion (ppb). The analyses were adjusted for known and suspected confounders.ResultsThe median age of the liver transplant recipients was 55 years (interquartile range (IQR) 46–64), and 58% were men. The liver transplant recipients had a higher median FENO50 than the controls [16 ppb (IQR 10–26) vs. 13 ppb (IQR 8–18.), p &lt; 0.001]. Furthermore, the liver transplant recipients had a higher prevalence of elevated FENO50 (for FENO50 ≥25 ppb 27% vs. 11%, p &lt; 0.001 and ≥50 ppb 4% vs. 2%, p = 0.02). The results were similar after adjusting for age, sex, smoking status, use of airway medication, and blood eosinophil counts [the adjusted odds ratio (OR) for FENO50 ≥25 ppb was 3.58 (95% CI: 2.50–5.15, p &lt; 0.0001) and the adjusted OR for FENO50 ≥50 ppb was 3.14 (95% CI: 1.37–7.20, p = 0.007)].ConclusionThe liver transplant recipients had elevated FENO50, implying increased eosinophilic airway inflammation. The clinical impact of this finding needs further investigation.
Tumor epitope spreading by a novel multivalent therapeutic cellular vaccine targeting cancer antigens to invariant NKT-triggered dendritic cells in situ
Authors: Yamasaki Satoru , Shimizu Kanako , Fujii Shin-ichiro 
Published: February 2024

IntroductionCancer is categorized into two types based on the microenvironment: cold and hot tumors. The former is challenging to stimulate through immunity. The immunogenicity of cancer relies on the quality and quantity of cancer antigens, whether recognized by T cells or not. Successful cancer immunotherapy hinges on the cancer cell type, antigenicity and subsequent immune reactions. The T cell response is particularly crucial for secondary epitope spreading, although the factors affecting these mechanisms remain unknown. Prostate cancer often becomes resistant to standard therapy despite identifying several antigens, placing it among immunologically cold tumors. We aim to leverage prostate cancer antigens to investigate the potential induction of epitope spreading in cold tumors. This study specifically focuses on identifying factors involved in secondary epitope spreading based on artificial adjuvant vector cell (aAVC) therapy, a method established as invariant natural killer T (iNKT) -licensed DC therapy.MethodsWe concentrated on three prostate cancer antigens (prostate-specific membrane antigen (PSMA), prostate-specific antigen (PSA), and prostatic acid phosphatase (PAP)). By introducing allogeneic cells with the antigen and murine CD1d mRNA, followed by α-galactosylceramide (α-GalCer) loading, we generated five types of aAVCs, i.e, monovalent, divalent and trivalent antigen-expressing aAVCs and four types of prostate antigen-expressing cold tumors. We evaluated iNKT activation and antigen-specific CD8+ T cell responses against tumor cells prompted by the aAVCs.ResultsOur study revealed that monovalent aAVCs, expressing a single prostate antigen, primed T cells for primary tumor antigens and also induced T cells targeting additional tumor antigens by triggering a tumor antigen-spreading response. When we investigated the immune response by trivalent aAVC (aAVC-PROS), aAVC-PROS therapy elicited multiple antigen-specific CD8+ T cells simultaneously. These CD8+ T cells exhibited both preventive and therapeutic effects against tumor progression.ConclusionsThe findings from this study highlight the promising role of tumor antigen-expressing aAVCs, in inducing efficient epitope spreading and generating robust immune responses against cancer. Our results also propose that multivalent antigen-expressing aAVCs present a promising therapeutic option and could be a more comprehensive therapy for treating cold tumors like prostate cancer.
Association of structural connectivity with functional brain network segregation in a middle-aged to elderly population
Authors: Schulz Maximilian , Petersen Marvin , Cheng Bastian , Thomalla Götz 
Published: February 2024

IntroductionThe deterioration of white matter pathways is one of the hallmarks of the ageing brain. In theory, this decrease in structural integrity leads to disconnection between regions of brain networks and thus to altered functional connectivity and a decrease in cognitive abilities. However, in many studies, associations between structural and functional connectivity are rather weak or not observed at all. System segregation, defined as the extent of partitioning between different resting state networks has increasingly gained attention in recent years as a new metric for functional changes in the aging brain. Yet there is a shortage of previous reports describing the association of structural integrity and functional segregation.MethodsTherefore, we used a large a large sample of 2,657 participants from the Hamburg City Health Study, a prospective population-based study including participants aged 46–78 years from the metropolitan region Hamburg, Germany. We reconstructed structural and functional connectomes to analyze whether there is an association between age-related differences in structural connectivity and functional segregation, and whether this association is stronger than between structural connectivity and functional connectivity. In a second step, we investigated the relationship between functional segregation and executive cognitive function and tested whether this association is stronger than that between functional connectivity and executive cognitive function.ResultsWe found a significant age-independent association between decreasing structural connectivity and decreasing functional segregation across the brain. In addition, decreasing functional segregation showed an association with decreasing executive cognitive function. On the contrary, no such association was observed between functional connectivity and structural connectivity or executive function.DiscussionThese results indicate that the segregation metric is a more sensitive biomarker of cognitive ageing than functional connectivity at the global level and offers a unique and more complementary network-based explanation.
YOLOv8-ACU: improved YOLOv8-pose for facial acupoint detection
Authors: Yuan Zijian , Shao Pengwei , Li Jinran , Wang Yinuo , Zhu Zixuan , Qiu Weijie , Chen Buqun , Tang Yan , Han Aiqing 
Published: February 2024

IntroductionAcupoint localization is integral to Traditional Chinese Medicine (TCM) acupuncture diagnosis and treatment. Employing intelligent detection models for recognizing facial acupoints can substantially enhance localization accuracy.MethodsThis study introduces an advancement in the YOLOv8-pose keypoint detection algorithm, tailored for facial acupoints, and named YOLOv8-ACU. This model enhances acupoint feature extraction by integrating ECA attention, replaces the original neck module with a lighter Slim-neck module, and improves the loss function for GIoU.ResultsThe YOLOv8-ACU model achieves impressive accuracy, with an mAP@0.5 of 97.5% and an mAP@0.5–0.95 of 76.9% on our self-constructed datasets. It also marks a reduction in model parameters by 0.44M, model size by 0.82 MB, and GFLOPs by 9.3%.DiscussionWith its enhanced recognition accuracy and efficiency, along with good generalization ability, YOLOv8-ACU provides significant reference value for facial acupoint localization and detection. This is particularly beneficial for Chinese medicine practitioners engaged in facial acupoint research and intelligent detection.
Pharmacokinetics and pharmacodynamics across infusion rates of intravenously administered nipocalimab: results of a phase 1, placebo-controlled study
Authors: Leu Jocelyn H. , Vermeulen An , Abbes Claudia , Arroyo Santiago , Denney William S. , Ling Leona E. 
Published: February 2024

IntroductionNipocalimab is a high-affinity, fully human, aglycosylated, effectorless, immunoglobulin G (IgG) 1 monoclonal antibody that targets the neonatal Fc receptor (FcRn), decreases systemic IgG including autoantibodies, and is under development in several IgG autoantibody- and alloantibody-mediated diseases, including generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, maternal-fetal medicine, and multiple other therapeutic areas. An initial phase 1 study with single and multiple ascending doses of nipocalimab infused intravenously (IV) over 2 h demonstrated dose-dependent serum pharmacokinetics and IgG reductions, with an adverse event (AE) profile comparable to placebo.MethodsThe current investigation evaluates the safety, tolerability, pharmacokinetics, and pharmacodynamics of single doses of nipocalimab across various IV infusion rates in a randomized, double-blind, placebo-controlled, sequential-dose study. Forty participants were randomized to receive nipocalimab 30 mg/kg over 60, 30, 15 or 7.5 min (0.5, 1, 2, or 4 mg/kg/min); nipocalimab 60 mg/kg over 15 min (4 mg/kg/min); or matching placebo.ResultsAt doses up to 60 mg/kg and infusion rates up to 4 mg/kg/min (maximum clinically feasible rate), single doses of nipocalimab were tolerable, with 12 (40%) participants experiencing AEs across nipocalimab cohorts compared with 1 (10%) participant in the placebo cohort. AEs deemed treatment related occurred in 6 (20%) participants receiving nipocalimab and 1 (10%) participant receiving placebo. None of the AEs were severe, and no participants discontinued treatment due to AEs. Nipocalimab provided consistent, dose-dependent serum pharmacokinetics and IgG reductions, regardless of infusion rate.DiscussionThis study supports the use of shortened durations of nipocalimab infusion for future studies.